Начало・Списък с акции・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

14.93 2.47

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.47

Максимум

14.8

Ключови измерители
By Trading Economics
Приходи	-176M 34M
Продажби	591K 78M
P/E Средно за сектора	7.112 64.641
EPS	0.25
Марж на печалбата	44.212
Служители	128
EBITDA	2.7M 50M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+7.55% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-92M 2B
Предишно отваряне	12.46
Предишно затваряне	14.93

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Aurinia Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 22:01 ч. UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1.08.2026 г., 00:01 ч. UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31.07.2026 г., 21:01 ч. UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30.07.2026 г., 20:31 ч. UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29.07.2026 г., 22:01 ч. UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28.07.2026 г., 19:36 ч. UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27.07.2026 г., 19:16 ч. UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24.07.2026 г., 18:26 ч. UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22.07.2026 г., 19:46 ч. UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21.07.2026 г., 19:16 ч. UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20.07.2026 г., 20:01 ч. UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Сравнение с други в отрасъла

Ценова промяна

Aurinia Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

7.55% нагоре

12-месечна прогноза

Среден 15.67 USD 7.55%

Висок 17 USD

Нисък 15 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Aurinia Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Aurinia Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.